Breakthrough in Childhood Lymphoma Treatment: China-Net Childhood Lymphoma Group Study Finds Promising Results

Strategic Insights -

A new study on childhood lymphoma, led by Capital Medical University, has yielded encouraging results in the treatment of diffuse large B-cell lymphoma (DLBCL) in Chinese children and adolescents. The study, conducted by the China-Net Childhood Lymphoma group, aimed to standardize diagnosis and treatment of childhood lymphoma and improve prognosis. The research found that the 5-year overall survival (OS) rate was 90.7% and the 5-year event-free survival (EFS) rate was 85.5%.

Key Takeaways:

  • The China-Net Childhood Lymphoma group B-NHL-2017 study is a prospective multi-center study conducted in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma and improving prognosis.
  • The study enrolled 138 children and adolescents, with a median age of disease diagnosis at 9.0 years, and followed them up for a median of 6.0 years.
  • A total of 12 events occurred in the study, including 7 deaths, and recurrence occurred in 6 patients at 14.9 months after initial treatment.
  • The study used Cox regression analysis and found that no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL.
  • The efficacy of the CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.

Statistics:

  • 138 children and adolescents were enrolled in the study.
  • The median age of disease diagnosis was 9.0 years (range: 2.3-15.5 years).
  • The 5-year overall survival (OS) rate was 90.7%.
  • The 5-year event-free survival (EFS) rate was 85.5%.
  • 12 events occurred in the study, including 7 deaths.
  • Recurrence occurred in 6 patients at 14.9 months after initial treatment.

Sources:

  • Clinical characteristics and treatment evaluation of diffuse large B-cell lymphoma in Chinese children and adolescents: a multicenter clinical study of China-Net childhood lymphoma group B-NHL-2017. Journal of Cancer Research and Clinical Oncology, 2025;151(7):220.
  • Capital Medical University, Beijing, 100045, People's Republic of China.
  • Fudan University Education Development Foundation.
  • Springer, One New York Plaza, Suite 4600, New York, Ny, United States.
  • ChiCTR1800020067 (Chinese Clinical Trial Registry).
  • The study was supported by the Fudan University Education Development Foundation.